What does ISO 10993-4 hemocompatibility testing mean in practice?
ISO 10993‑4 assesses how a medical device interacts with blood and whether hemolytic, coagulation‑related or immunological reactions may occur. The standard provides a risk‑based framework for selecting relevant biological endpoints and applies to any device with direct or indirect blood contact, including catheters, dialysis systems, blood tubing and implantable cardiovascular devices.
The choice of endpoints depends on the type and duration of blood contact. Typical parameters include hemolysis, coagulation activation, thrombogenicity, platelet activation and complement activation. These endpoints cover different hematological and hemostatic mechanisms and support a clinically meaningful safety evaluation. Devices with short‑term extracorporeal contact may require different testing priorities than long‑term intravascular implants.
The testing strategy and sample preparation are based on the requirements of ISO 10993-4 and the specific properties of the medical device. Blood contact is simulated using suitable static or dynamic in-vitro systems that replicate the geometry, surface properties, and contact time of the product as realistically as possible. This results in reproducible data directly relevant to later clinical use.
Hemocompatibility results feed into the ISO 10993‑1 Biological Evaluation. Non‑reactive findings support a low hemocompatibility‑related risk, whereas reactive or borderline results require toxicological and clinical interpretation. Depending on the outcome, design modifications, material changes or additional testing may be necessary.
Norm criteria – at a glance
| Norm criterion | Requirement / content | Note |
|---|---|---|
| Objective | Assess blood interactions | ISO 10993-4 framework |
| Endpoints | e.g., hemolysis, coagulation, complement | Risk-based |
| Sample preparation | ISO 10993-12 aligned | Reflect blood contact |
| Reporting | QES-signed | MDR-ready |
| Integration | Input ISO 10993-1 | Assessed externally |
How we test your medical device – step by step
- Request a quote by phone or online. Key inputs: device, materials/components, contact type and exposure duration, and the device condition (e.g., sterilized/reprocessed).
- Send your device after accepting the quote. Please provide the sample in the marketed/used state where possible (including reprocessed state if applicable).
- Upon receipt, we start testing and document sample logistics and - where relevant - ISO 10993-12 aligned preparation/extraction parameters.
- We perform ISO 10993-4 hemocompatibility testing and select endpoints risk-based based on type and duration of blood contact.
- You receive a digital, QES-signed report with professional interpretation. Upon request, we coordinate next steps through external toxicology (ISO 10993-17) and the ISO 10993-1 Biological Evaluation.
Why HygCen?
- DAkkS accredited testing laboratory (DIN EN ISO/IEC 17025) with GLP-compliant processes.
- Risk-based study design aligned with intended contact type, duration and use.
- Testing in the original state, including relevant processing/sterilization/reprocessing influences.
- Digital, QES-signed report with expert interpretation for MDR technical documentation.
- One-stop coordination: we manage interfaces to independent toxicologists for ISO 10993-17 and the ISO 10993-1 Biological Evaluation when needed.
ISO 10993‑4 is required whenever a device has direct or indirect blood contact, such as catheters, dialysis systems, blood lines or implantable cardiovascular devices. The standard provides a structured framework for evaluating blood‑device interactions, including hemolysis, coagulation and complement activation. Endpoint selection is risk‑based and considers exposure duration and clinical scenario, ensuring systematic identification of hemocompatibility risks in line with ISO 14971.
Typical endpoints include hemolysis, coagulation activation, thrombogenicity, platelet activation and complement activation. The precise selection depends on device category, blood contact duration and intended clinical use. A well‑designed endpoint panel addresses all relevant hematological impacts that could influence patient safety.
Blood contact is represented using static or dynamic in‑vitro systems tailored to the device’s geometry, surface characteristics and intended contact time. Sample preparation follows ISO 10993‑12 to ensure sterilization and processing steps are reflected. This ensures that exposure conditions closely mirror clinical use, enabling meaningful, reviewable results.
Hemocompatibility results are integrated into the ISO 10993‑1 Biological Evaluation as a dedicated evidence block. Non‑reactive findings support acceptable risk, while reactive outcomes must be evaluated clinically and toxicologically. Depending on the severity, results may lead to material changes, design modifications or further testing.
Timelines depend on the number of endpoints, access to suitable blood samples and complexity of the study design. Additional time may be needed for system validation, sample preparation and specialized laboratory analyses. Project‑specific schedules support regulatory planning and submission timelines.
Related links
ISO 10993-12 – Sample preparation & reference materials, ISO 10993-18 – Chemical characterization, ISO 10993-10 – Skin sensitization, ISO 10993-5 – Cytotoxicity, ISO 10993-23 – Irritation, ISO 10993-3 – Genotoxicity, Pyrogenicity & endotoxin – incl. ISO 10993-11 coordination, ISO 10993-1 – Biological Evaluation